Counts 3992 text words. 225 abstract words. 5 figures and 2 tables. 68 references.
Introduction
Multiple myeloma is a plasma cell neoplasm characterised by lytic bone lesions, hypercalcemia, renal impairment and bone marrow failure. Although outcomes have improved in recent years with the introduction of novel agents, the disease remains incurable and clinical responses display considerable heterogeneity. 1,2 Further improvements will not only come from introduction of new drugs but from better use of existing drugs. Younger, fitter patients are usually treated with a drug combination involving a proteasome inhibitor (PI) and/or an immunomodulatory drug (IMiD) followed by high-dose melphalan therapy with autologous stem cell transplant (ASCT). For transplant-ineligible patients, recent trial data suggest that the treatment of choice may be a combination of the PI, bortezomib (Velcade, Millennium Pharmaceuticals, Cambridge, MA), the IMiD, lenalidomide (Revlimid, Celgene, Summit, NJ), and dexamethasone (VRD). 3 However, this combination is expensive and is not funded in most countries outside the United States (US). Furthermore, for very frail patients, three-drug combinations may prove too toxic.
It is possible that treatment outcomes in myeloma might be improved by the application of precision medicine, i.e. the rational selection of drugs based on the biology of each patient's tumour. Several studies have demonstrated the potential of using transcriptomic data to derive prognostic information in myeloma. [4] [5] [6] Signatures can be usefully combined, 7 but are generally agnostic to treatment 4, 5, [8] [9] [10] [11] [12] and their main clinical utility is likely to be the identification of patients who may benefit from trials for high-risk disease. We sought to derive a signature that could predict responses to specific therapies.
The phase II study of Bortezomib, Adriamycin, and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT (PADIMAC) was designed to examine whether patients with good responses to PAD could safely avoid upfront ASCT. We employed RNAsequencing (RNA-Seq) on available good-quality RNA from enrolled patients and derived a training dataset from patients with sustained deep responses in the absence of ASCT. We thus generated a signature for predicting bortezomib-responsiveness in myeloma patients not receiving ASCT. When tested in independent datasets, the signature performed well, identifying patients who benefited from bortezomib-based treatment in the absence of an
IMiD. Furthermore, when tested on lenalidomide-dexamethasone (RD) treated patients, the signature performed in a reciprocal fashion, suggesting that it could be used as a binary classifier to choose between bortezomib-based treatment and RD. Patients who had been treated correctly according to the signature classification had a superior survival to those who had not. Indeed, in the relating Clinical outcomes in Multiple Myeloma to personal assessment of genetic profile (CoMMpass) dataset, correctly treated patients receiving either bortezomib-based therapy (without IMiD) or receiving RD (without bortezomib) had a noninferior survival to those treated with VRD. This suggests that our signature could be employed to improve the safety and cost-effectiveness of myeloma therapy without compromising outcomes.
Materials and Methods

Sample accrual and processing and data generation
Sample accrual and RNA isolation
RNA of sufficient quality for RNA-Seq was available from 44 patients treated on the PADIMAC trial (ISRCTN03381785). The trial protocol is described in the Supplementary Materials. PADIMAC was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and was approved by the NHS National Research Ethics Service. Participants provided written informed consent. Patient registration and trial management were performed by the Cancer Research UK and University College London Cancer Trials Centre. All patients had newly diagnosed untreated myeloma, Eastern Cooperative Oncology Group performance status 0-3, and were eligible for ASCT. Total RNA was isolated using standard methodology, as described in the Supplementary Materials.
Identification of mutations and gene expression
Standard methods were used to identify mutations and determine gene expression. Detailed methodology is described in Table S1 and the Supplementary Materials. Briefly, reads were mapped with TopHat 13 and aligned with Samtools. 14 Single nucleotide variants (SNVs) and small indels were identified using VarScan 15, 16 and RNA fusions were identified using FusionCatcher. 17 Read counts were generated with the Rsubread package. 18, 19 Raw and count level data have been uploaded to Gene Expression Omnibus (GEO), reference GSE116324.
Differentially expressed genes were identified using DESeq2 20-22 and the Gage 23 and Pathview 24,25 packages were used for pathway analysis.
Machine learning
Selection of test datasets
Test RNA-Seq datasets were derived from CoMMpass (https://research.themmrf.org/). Microarray test sets were obtained for relapsed/refractory patients treated with bortezomib 26 (GEO reference GSE9782), plasma cell leukemia (PCL) patients treated with RD 27 (GSE39925), and newly diagnosed myeloma patients treated with PAD followed by ASCT 28 (GSE19784). We refer to these data as the Millennium, PCL, and HOVON/GMMG datasets, respectively. pre-processing, training, validation, and testing RNA-Seq counts were normalized and corrected for heteroscedasity according to published methods. [29] [30] [31] [32] [33] [34] [35] Potential signature genes were identified from the PADIMAC dataset by an empirical Bayes method, 36 then selected as described using synthetic annealing 37 with an error rate determined by a support vector machine implemented from the e1071 package (https://cran.r-project.org/web/packages/e1071/index.html).
Data
Signature assignments were made using the Largest Margin Nearest Neighbors (LMNN) algorithm. 38 Performance within the PADIMAC dataset was checked by ten-fold crossvalidation. For external testing, all PADIMAC data were used for training, with an initial 50:50 split into a training and internal validation set that was fixed for all testing. R and Matlab scripts replicating this process have been included with the Supplementary Materials.
All the CoMMpass, Millennium, PCL, or HOVON/GMMG data were used for testing. To determine the robustness of the signature performance in each case, a form of permutation testing was used, as described in the Supplementary Materials.
Statistical considerations
Null and observed assignments were compared using the Mann-Whitney-Wilcoxon test.
Survival was compared using the Cox proportional hazards model. P-values of 0.05 or less were considered significant.
Results
Initial assessment of PADIMAC data excludes a mutation-based classifier
We performed RNA-Seq on purified CD138+ plasma cells from a cohort of 44 patients treated on the PADIMAC trial. Clinical data are shown in Table S2 . We first explored the possibility of using a mutation-based classifier for bortezomib-responsiveness. We identified fusion and SNV transcripts from the RNA-Seq data (Figures 1A and 1B and Tables S3 and   S4 ). There were 0-8 fusions in each sample with a median of one ( Figure 1A ). Expected IgH-WHSC1 fusions were detected from t(4;14) patients (Table S3 ). There was a median of nine SNVs per patient in coding regions, which is lower than seen in previous DNA sequencing studies. [39] [40] [41] [42] This may reflect reduced expression from mutant alleles 43 as well as a failure to detect mutations in the furthest 5' regions of some genes. Nevertheless, we identified many of the known driver mutations in myeloma ( Figure 1B and Table S4 ). Other known drivers were not mutated in our cohort, which may be related to sample size or may reflect lack of expression of mutated alleles. 43 Overall, 45.5% of patients in the cohort achieved very good partial remission (VGPR) or better following PAD induction (Table S2 ). We defined a "bortezomib-good" group, namely patients who achieved a VGPR or better and who were progression-free at one year without ASCT (13/44; 29.5%). We termed the remaining patients "bortezomib-standard" (31/44; 70.5%). There were no associations between these groups and age, International Staging System (ISS), or myeloma type (Table S5 ). We also saw no significant associations between bortezomib-responsiveness and the presence of key cytogenetic, SNV, and translocation events (Table S6 ). There were trends towards significant associations between the bortezomib-good group and (a) the presence of any translocation and (b) the presence of a beta2-microglobulin translocation (Table S6 ). However, we did not feel that these associations were sufficiently strong for predicting clinical outcomes. We therefore turned to expression profiling.
Derivation of a seven-gene bortezomib-response signature
Expression of target genes known to be differentially expressed using microarray 44 and qPCR 45 technologies in the Translocation-Cyclin D (TC) classification was consistent with that previously described ( Figure 1C ), 44 confirming the utility of RNA-Seq for measuring relative gene expression in myeloma. We therefore proceeded to identify a gene signature for bortezomib-responsiveness. We ranked potential genes using synthetic annealing 37 (Figures S1 and S2). Derived signatures comprising 4-11 genes performed better than permuted assignments in cross-validation of PADIMAC data using the LMNN algorithm (Figures S3 and S4; Matthews Correlation Coefficient (MCC) median 0.55 versus -0.045, Mann-Whitney U 0, p=0.00090, two-tailed, Figure S4A ; F-measure median 0.67 versus 0.25, Mann-Whitney U 0, p=0.00090, two-tailed, Figure S4B ). Of these signatures, the best performing was the seven-gene signature (Figure 2A ). As training of the LMNN algorithm parameters involves splitting the training set into a training and internal validation set ( Figure S2 ), we checked that the seven-gene signature was robust by performing multiple (n=100) training/validation splits and comparing performance with permuted assignments (n=100) during crossvalidation. The observed assignments had higher MCC and F-measures than the null assignments (MCC median 0.50 versus 0.0054, Mann-Whitney U 8, p=2.85x10 -34 , two-tailed, Figure 2B ; F-measure median 0.64 versus 0.26, Mann-Whitney U 3, p=2.42x10 -34 , twotailed, Figure 2C ), confirming that the signature performed well regardless of the training/validation split.
The genes comprising the signature are EMC9, FAM171B, PLEK, MYO9B, RCN3, FLNB, KIF1C (Table S7 ). We did not see enrichment of these genes within the pathway genesets from the Molecular Signatures Database [46] [47] [48] (http://software.broadinstitute.org/gsea/msigdb/annotate.jsp; C2 collection). However, at least three of the proteins (EMC9, RCN3, and KIF1C) are associated with the endoplasmic reticulum and three others (PLEK, MYO9B, and FLNB) interact with actin filaments.
Furthermore, three genes (EMC9, MYO9B, and KIF1C) associate positively with proliferation in myeloma. 10 Despite the lack of objective pathway enrichment in our signature, supervised analysis of the RNA-Seq data as a whole did reveal pathways upregulated in the bortezomib-good patients (Table S8 ).
The seven-gene signature is predictive of outcome of bortezomib-treated patients in the independent CoMMpass dataset
To enable testing of our signature in an independent external dataset, we extracted RNA-Seq data from CoMMpass. We selected previously untreated patients who did not proceed to ASCT, as none of the bortezomib-good patients had received transplant. There were 147 such bortezomib-treated patients (who had received no IMiD), 40 RD patients, and 208 VRD patients for whom RNA-Seq data were available (Tables S9-S11). There were a few differences in clinical features between the groups. PADIMAC patients, being transplanteligible, were younger than all the CoMMpass cohorts ( Figures S5-S7 ). VRD-treated patients in CoMMpass were younger than the bortezomib-treated and RD cohorts (Figures S9 and S10). RD-treated patients had higher rates of del13 than PADIMAC or bortezomib-treated patients and a lower rate of t(4;14) than bortezomib-treated patients (figures S6 and S8).
There were no differences in ISS stage between the groups (figures S5-S10).
We trained our seven-gene signature on the PADIMAC data and tested its ability to identify patients who would benefit from bortezomib-based therapy within CoMMpass ( Figure S11 ).
Patients who received bortezomib-based therapy and were assigned to the bortezomib-good group had a better progression-free survival (PFS) than those assigned to the bortezomibstandard group ( Figure 2D ; Table 1 , row 1). The randomization seed for the PADIMAC training/validation split had been fixed prior to testing. To ensure that the predictive ability of the signature was robust, we performed multiple additional training/validation splits of the PADIMAC training set and compared the resulting assignments in the CoMMpass test set with permuted assignments that formed a null dataset. As expected for a robust signature, hazard ratios (HRs) for the predicted bortezomib-good patients were lower than the HRs from random predictions ( Figure 2E ; Table 2 , row 1).
The seven-gene signature has reciprocal performance in RD-treated patients and has the potential to select therapy
To distinguish between the signature acting as a general predictor of good-prognosis disease and as a specific predictor of bortezomib-sensitive disease, we tested it in RD-treated patients. We reasoned that, if the signature were bortezomib-specific, the survival of RDpatients assigned to the bortezomib-good would be no better than those assigned to the bortezomib-standard groups. To our surprise, RD-treated patients assigned to the bortezomibgood group in fact had an inferior PFS to those assigned to the bortezomib-standard group ( Figure 3A ; Table 1 , row 2). Whilst the difference was not significant, those assigned to the bortezomib-good group across repeated training/validation splits had consistently lower survival, with higher hazard ratios (HRs) than those obtained by permuting the assignments ( Figure 3B ; Table 2 , row 2).
The implication of these findings is that patients predicted to do well with bortezomib by our signature do poorly when treated with RD and vice versa. Hence the seven-gene signature could be used as a binary classifier to rationally choose between bortezomib-based therapy and RD. To test this, we selected CoMMpass patients treated with bortezomib-based therapy or with RD and assigned each to a bortezomib-best or lenalidomide-best group. We then compared survival between those patients who received the predicted best treatment with those who did not. Patients who received the correct therapy had a superior PFS ( Figure 3C ; Table 1 , row 3) and overall survival (OS; Figure 3D ; Table 1 , row 4). The incorrectly treated patients had a median PFS of 20.1 months and a median OS of 31.2 months, whereas the median PFS and OS were not reached for correctly treated patients. These predictions were again robust to the initial training/validation split of the PADIMAC dataset ( Figure S12 ; Table 2 , rows 3 and 4).
We excluded the possibility that the signature was acting as a surrogate for clinical features.
We saw no association between signature assignment and key cytogenetic events (p=0.13;
Fisher's exact test; Table S12 ) and in multivariate Cox regression, ideal treatment according to the signature retained significance for survival when age, ISS, or myeloma subtype were taken into account (Tables S13, rows 1 and 2).
Because of the finding of proliferative genes in our signature, we also wanted to check that it was not acting as a surrogate for the gene-expression based proliferation index (GPI50) signature 10 or other prognostic signatures. As these signatures have not, to our knowledge, been applied to RNA-Seq data previously, we first tested that they could be applied to the CoMMpass dataset. Indeed, when all of the GPI50, University of Arkansas for Medical Sciences (UAMS70), Erasmus University Medical Centre (EMC92), and Intergroupe
Francophone du Myélome (IFM15) signatures 4-6,10 were applied to CoMMpass, the distribution of scores was similar to that seen in microarray datasets 5 (Figures S13A, S13C, S3E, and S13G). Furthermore, all signatures retained prognostic significance using thresholds equivalent to those previously published 5 (Figures S13B, S13D, S13F, S13H). Having established that these prognostic signatures were effective in RNA-Seq data, we examined whether there was any association between their assignments and the assignments of our seven-gene signature. None was seen (Table S14 ). Furthermore, receiving ideal treatment according to the seven-gene signature retained its prognostic significance even in a multivariate analysis including these signatures (Table S15) .
A recent trial reported the superiority of VRD over RD in transplant-ineligible patients, 3 but VRD treatment is not currently funded widely outside the US. We wondered whether rationally selected therapy could be a cost-effective alternative to this gold-standard treatment. We first demonstrated that VRD was superior to unselected bortezomib-based treatment or RD in CoMMpass ( Figure S14 ; Table 1 , rows 5 and 6). We then compared the survival of patients treated correctly according to our signature with the survival of all patients treated with VRD in CoMMpass. There was no statistically significant difference in OS ( Figure 3E ; Table 1 , row 7) or PFS ( Figure S15A ; Table 1 , row 8) between patients treated correctly with bortezomib or RD and those treated with VRD. This was also true in a multivariate analysis incorporating clinical features (Table S13 , rows 3 and 4). We also compared the outcome of CoMMpass patients treated correctly with bortezomib according to the signature and all patients receiving bortezomib-based induction followed by ASCT.
Interestingly, there was no significant difference in survival between the two groups ( Figure   S16 ; Table 1 rows 9 and 10), although there was weak evidence of an effect implying longer OS with transplant.
We hypothesized that the seven-gene signature should have minimal predictive ability in VRD-treated patients. As expected, we saw no difference between the outcomes for patients assigned to the bortezomib-best or lenalidomide-best groups when those patients were treated with VRD. This was true both for OS ( Figure 3F ; Table 1 , row 11) and for PFS ( Figure   S15B ; Table 1 , row 12). This lack of predictive ability was also seen in multivariate analyses incorporating clinical features (Table S13 , rows 5 and 6).
The seven-gene signature performs well in other independent datasets
We were keen to test how our signature would perform in other non-transplant settings, such as relapsed disease. However, we were limited by the availability of publicly-available RNA-Seq data, so turned to microarray data. There were two suitable datasets available. One comprised samples from patients with relapsed-refractory myeloma treated with single-agent bortezomib 26 (the Millennium dataset). The second contained transcriptomic data from a small series of patients with PCL treated with RD 27 (the PCL dataset). We reasoned that, within the Millennium dataset, patients assigned to the bortezomib-best class should have a better survival, whereas within the PCL dataset, those assigned to the lenalidomide-best class should have the superior outcome.
Signature assignments behaved as predicted. In the Millennium dataset the bortezomib-best group had a superior PFS ( Figure 4A ; Table 1 , row 9) and OS ( Figure 4B ; Table 1 , row 10) to the lenalidomide-best group. These results were robust to training/validation splits ( Figure   4C ; Table 2 , rows 5 and 6). In the PCL dataset, those predicted to be in the lenalidomide-best group had a superior PFS ( Figure 4D ; Table 1 , row 11) and OS ( Figure 4E ; Table 1, row 12) than patients assigned to the bortezomib-best group. Again, the signature was robust, with little influence from the training/validation split ( Figure 4F ; Table 2 , rows 7 and 8).
The seven-gene signature loses predictive power in patients proceeding to ASCT
The bortezomib-good patients in the PADIMAC training set avoided ASCT because of their good response, according to trial protocol. We had thus far confined testing in external datasets to patients who had not had ASCT. We wondered whether the signature would retain its predictive power in patients proceeding to ASCT or whether transplant would overcome the survival differences between correctly and incorrectly treated patients. The HOVON-64/GMMG-HD4 phase III trial 49 compared patients with newly diagnosed myeloma treated with conventional chemotherapy versus those treated with PAD. Both groups of patients proceeded to ASCT.
We used our signature to make bortezomib-best and lenalidomide-best assignments in patients who had received PAD. We reasoned that, if the signature retained its predictive power in the ASCT setting, we would see superior survival in those patients assigned to the bortezomib-best group. This was not the case, however, and we saw no significant difference in either PFS ( Figure 5A ; Table 1 , row 13) or OS ( Figure 5B ; Table 1 , row 14) between the different signature assignments.
As a further check for the specificity of the signature, we also tested its predictive value in the dexamethasone-only arm. As anticipated, there was no difference in PFS between those patients predicted to be bortezomib-good and those predicted to be lenalidomide-good ( Figure S17A ). However, patients predicted to be bortezomib-good had a superior OS in this arm ( Figure S17B ). This is likely to be because patients receiving dexamethasone were eligible to receive cross-over bortezomib upon disease progression.
Discussion
If it can be realized, precision cancer medicine will benefit patients in terms of improved efficacy and reduced toxicity and will benefit society in terms of better management of stretched drug budgets. Transcriptomics has considerable promise in this area. 50 There are signatures that predict for overall prognosis in cancer, 51-62 including myeloma, 4-12 and signatures that predict response to individual therapies. 63-67 However, we are not aware of any published signature that can be used to rationally select between different active cancer therapies. Remarkable improvements in myeloma outcome over recent years have been seen thanks to the introduction of multiple novel agents, but this has been associated with increasing costs of treatment. 68 Therefore, precision medicine is arguably of particular importance in this disease to help navigate through the increasing armamentarium of available therapies.
Herein, we describe the derivation and testing of a seven-gene signature that can be used to select between bortezomib-based or RD therapy in myeloma patients not undergoing ASCT. If the outcome of rationally selected bortezomib-or lenalidomide-based therapy is equivalent to that of VRD, it would be important to consider why this might be. It may be that many patients treated with VRD are predominantly benefiting from just the bortezomib or the lenalidomide. Alternatively, it might be that any gains in combining the drugs are offset by increased toxicity, particularly in older or frailer patients. It is important to note that the reciprocal performance that we observe is an intrinsic property of the signature and not simply because bortezomib-sensitivity is automatically associated with lenalidomideresistance (and vice versa). This is clearly not the case in clinical practice, nor is it consistent with the existence of multiple treatment-agnostic prognostic signatures in myeloma.
Although PADIMAC was a trial for transplant-eligible patients, the signature was trained on patients who had had a good response in the absence of ASCT. Therefore, our initial test set comprised patients who were transplant-ineligible (there were no datasets from transplanteligible patients who did not proceed to transplant). Transplant-ineligible patients would be the most obvious to benefit following successful translation of the signature to the clinic.
When tested in transplant-eligible patients who had received PAD and ASCT in the We believe that our signature has the potential to move the myeloma field towards rational therapy decisions for transplant-ineligible patients in the future. It is essential that myeloma genomic datasets with relevant clinical outcome data continue to be made publicly available to allow refinement and prospective validation of these approaches. This will require the ongoing support of the myeloma research community. All signature assignments were based on the seven-gene signature. Correctly-treated patients (rows 3-6) were those predicted by the signature as lenalidomide-best and who were treated with RD or those predicted as bortezomib-best and treated with bortezomib-based therapy. The datasets are CoMMpass (C), Millennium (M), plasma cell leukemia (PCL), or HOVON/GMMG (H). The numbers in the first group in the comparison (n1) and second group in the comparison (n2) are given. The hazard ratio (HR) is that of the second group versus the first group. CIconfidence interval. *The HR for the PCL group is not defined because all patients in group 2 progressed before any progressions in group 1 (row 11) or because there were no deaths in group 1 (row 12). 
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